Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v3.10.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 15, 2011
Apr. 30, 2018
Mar. 31, 2017
Jun. 30, 2017
Dec. 31, 2018
Dec. 31, 2017
Commitments And Contingencies [Line Items]            
Accrued Liabilities, Current         $ 385,000 $ 712,000
Revenues         2,216,000 2,019,000
Litigation Settlement, Expense   $ 125,000        
CellularityInc [Member]            
Commitments And Contingencies [Line Items]            
Royalty Expense         381,000 818,000
Accrued Liabilities, Current         $ 0 $ 227,000
Choice TherapeuticsInc [Member]            
Commitments And Contingencies [Line Items]            
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares       132,000    
Business Combination, Contingent Consideration, Liability       $ 500,000    
Installment Two [Member]            
Commitments And Contingencies [Line Items]            
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets     3.5      
Installment Two [Member] | Two Thousand Fifteen Mist Therapy [Member]            
Commitments And Contingencies [Line Items]            
Revenues     $ 10,500,000      
Installment Two [Member] | Two Thousands Sixteen Mist Therapy [Member]            
Commitments And Contingencies [Line Items]            
Revenues     10,200,000      
Installment Two [Member] | Contingent Consideration [Member]            
Commitments And Contingencies [Line Items]            
Payments to Acquire Businesses, Gross     $ 675,000      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares     101,000      
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned     $ 675,000      
Noble Fiber Technologies License Agreement [Member]            
Commitments And Contingencies [Line Items]            
Royalty Fee Percentage 9.75%